The latest results from the STAMPEDE trial have shown immediate radiotherapy with standard hormone therapy could increase the survival of thousands of men diagnosed with advanced prostate cancer that hasn't spread too widely. We're now calling for the treatment to be offered to these men as standard on the NHS.
As part of our Research Innovation Awards, we’re funding Professor Claire Lewis at the University of Sheffield to see if it's possible to train men’s own immune systems to fight back at prostate cancer and prevent it from returning. She explains the fascinating 'Trojan horse' science behind this new example of Immunotherapy research.
The Institute of Cancer Research has discovered a genetic mutation in samples of some men's tumours that could make them particularly susceptible to immunotherapy treatment. The researchers are now committed to running clinical trials to prove if their theory is right.
A five-year early-stage study of high-intensity focused ultrasound resulted in tumour progression being halted in men with intermediate-risk, localised prostate cancer. But more evidence is needed to prove its benefits hold up against existing treatment options and for all men with the disease.
Preventing resistance to hormone therapy is a key goal for researchers trying to improve prostate cancer treatment. Now, research funded by us – thanks to your donations – has revealed that the immune system could have a part to play.
We're calling on the NHS to make rollout of the revolutionary diagnostic technique for prostate cancer a priority, after new data shows a huge variation in the availability and quality of mpMRI scans across the UK. Check out how your local hospitals are performing in our online map, and find out more about the first clinical consensus on mpMRI we've helped to create.
Across the papers today is news of a 'spit test' to help diagnose prostate cancer. It’s a promising step forward in genetics, but we still need better tests for diagnosis.
An early-stage trial of the immunotherapy drug, pembrolizumab, has proven it to be effective for a small number of men with incurable disease. We take a closer a look at how it works and what we're doing to bring the benefits of immunotherapy to many more men with prostate cancer.
New research backed by us and the Movember Foundation has shown that a type of ultrasound scan, which can detect the stiffness of the prostate, may be able to spot aggressive cancer.
An international group of researchers has identified dozens more genes that are potentially involved in the growth of prostate cancer. This could lead to new ways of treating the disease.